| Pharmaceutical Processing | Hold Removed on Head & Neck Cancer Trial Pharmaceutical Processing CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the company's Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has ... Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move ForwardTheStreet.com FDA gives Ergomed's partner green light to resume phase III cancer studyProactive Investors UK As FDA lifts clinical hold, CEL-SCI's long journey to approval marches onThe Pharma Letter (registration) Endpoints News -Stock Market Wire -CNA Finance (press release) all 14 news articles » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uHsjr4
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,